American Association for Cancer Research
crc-22-0329-s06.pdf (199.7 kB)

Figure S6 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

Download (199.7 kB)
journal contribution
posted on 2023-07-12, 14:20 authored by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, Jashodeep Datta, Eli Gilboa, Nipun B. Merchant, Nagaraj S. Nagathihalli

PD-L1 expression in Uro A or PI3Ki treated KPC cells.


HHS | NIH | National Cancer Institute (NCI)

Florida Department of Health

American Cancer Society (ACS)



Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.